NCT07340138 is a Phase 1 clinical trial of Pelabresib in Primary Myelofibrosis (PMF), sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT07340138?

NCT07340138 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT07340138?

Interventions in NCT07340138: Pelabresib, Ruxolitinib.

What condition does NCT07340138 study?

NCT07340138 studies Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF).

Is NCT07340138 still recruiting?

NCT07340138 is currently not yet recruiting. Last updated 2 April 2026.

Last reviewed 2026-04-02 · How we verify

NCT07340138

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Not yet recruiting Phase 1 Last updated 2 April 2026

What this trial tests

Phase 1 trial testing Pelabresib in Primary Myelofibrosis (PMF) in 6 participants. Not yet recruiting.

Timeline

7 May 2026

Primary endpoint
16 November 2026

18 December 2030

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	7 May 2026
Primary completion	16 November 2026
Estimated completion	18 December 2030

Drugs / interventions tested

Pelabresib — full drug profile →
Ruxolitinib (RUXOLITINIB) — full drug profile →

Conditions studied

Primary Myelofibrosis (PMF) — all drugs for Primary Myelofibrosis (PMF) →
Post-polycythemia Vera Myelofibrosis (Post-PV MF) — all drugs for Post-polycythemia Vera Myelofibrosis (Post-PV MF) →
Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) — all drugs for Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Primary Myelofibrosis (PMF) or Post-polycythemia Vera Myelofibrosis (Post-PV MF). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Pelabresib

Trials testing the same drug.

NCT07357727 — A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) · Phase 3 · recruiting
NCT06401356 — An Extension Study for Patients Previously Enrolled in Studies With Pelabresib · Phase 3 · recruiting
NCT05391022 — Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies · Phase 1 · completed
NCT04603495 — Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) · Phase 3 · active not recruiting
NCT02158858 — A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignanc · Phase 1, PHASE2 · completed

Other recruiting trials for Primary Myelofibrosis (PMF)

Currently open trials in the same condition.

NCT07357727 — A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) · Phase 3 · recruiting
NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting
NCT03441113 — Extended Access of Momelotinib in Adults With Myelofibrosis · Phase 2 · active not recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07340138 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 2 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07340138.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing